Low Utilization of Surgical Resection for Locally Advanced Pancreatic Cancer

Despite the positive outcomes reported by high-volume international centers, a multicenter retrospective study in the Netherlands found that surgical resection for locally advanced pancreatic cancer (LAPC) following induction chemotherapy is infrequently performed. Out of 142 patients who underwent resection, only 34.5% met the national comprehensive cancer network criteria. The most commonly used chemotherapy was FOLFIRINOX, and venous and arterial resections were performed in a minority of patients. The study also revealed acceptable morbidity and mortality rates, with a median overall survival of 26 months and a 5-year survival rate of 18%.